92 Countries to Receive Moderna's COVID-19 Vaccine
Massachusetts-based Moderna, Inc. today announced an agreement with Gavi, the Vaccine Alliance, to supply up to 500 million doses of the mRNA COVID-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021, to 92 low- and middle-income countries.
All doses are offered at Moderna’s lowest tiered price, in line with the Company’s global access commitments.
Through this agreement, Gavi retains the option to procure 466 million additional doses in 2022.
“We are very pleased to sign this new agreement with Moderna, giving COVAX Facility participants access to yet another highly efficacious vaccine,” said Dr. Seth Berkley, CEO of Gavi, in a press release.
The COVID-19 Vaccine Moderna is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike protein co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Diseases Vaccine Research Center. This experimental vaccine has been Authorized by the U.S. FDA but not Approved.